Nonionic surfactant vesicles for delivery of RNAi therapeutics

Nanomedicine

Volumn 8, Issue 11, 2013, Pages 1865-1873

  Paecharoenchai, Orapan ^a,b   Teng, Lesheng ^c   Yung, Bryant C ^b   Teng, Lirong ^c   Opanasopit, Praneet ^a   Lee, Robert J ^b,c  

^a SILPAKORN UNIVERSITY   (Thailand)

^b OHIO STATE UNIVERSITY   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

gene delivery; niosome; nonionic surfactant vesicle; siRNA delivery

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIGLAUCOMA AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA GALACTOSIDASE; DNA VACCINE; HORMONE; INSULIN; LIPOFECTAMINE; LOCAL ANESTHETIC AGENT; LUCIFERASE; MUSCLE RELAXANT AGENT; NIOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; PLASMID DNA; SMALL INTERFERING RNA; STEROID; VASOPRESSIN; LIPOSOME; SURFACTANT;

CYTOPLASM; GENE EXPRESSION; GENE SILENCING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; REVIEW; RNA INTERFERENCE; ANIMAL; CHEMISTRY; PHYSIOLOGY;

ANIMALS; HUMANS; LIPOSOMES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SURFACE-ACTIVE AGENTS;

EID: 84887233501     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.155     Document Type: Review

References (64)

1. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 5, 8-20 (2009).
2. Wang J, Lu Z, Wientjes GM, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12(4), 492-503 (2010).
3. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med. 267(1), 9-21 (2010).
4. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43, 13348-13356 (2004). (Pubitemid 39391135)
5. Deleavey GF, Damha MJ. Designing chemically modifed oligonucleotides for targeted gene silencing. Chem. Biol. 19(8), 937-954 (2012).
6. Vicentini FT, Borgheti-Cardoso LN, Depieri LV et al. Delivery systems and local administration routes for therapeutic siRNA. Pharm. Res. 30(4), 915-931 (2013).
7. Rhinn H, Largeau C, Bigey P et al. How to make siRNA lipoplexes effcient? Add a DNA cargo. Biochim. Biophys. Acta 1790, 219-230 (2009).
8. Lin PJ, Tam YY, Hafez I et al. Infuence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine 9(2), 233-246 (2013).
9. Ho EA, Osooly M, Strutt D et al. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. J. Pharm. Sci. 102(1), 227-236 (2013).
10. Whitehead KA, Matthews J, Chang PH et al. In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. Am. Chem. Soc. Nano 6(8), 6922-6929 (2012).
11. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172-176 (2010).
12. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation infuences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107(2), 276-287 (2005). (Pubitemid 41316290)
13. Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J. Biol. Med. 85(2), 187-200 (2012).
14. David S, Pitard B, Beno JP, Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62, 100-114 (2010).
15. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
16. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int. J. Pharm. 219, 61-72 (2001).
17. Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J. Pharm. Pharm. Sci. 5, 220-225 (2002). (Pubitemid 37211713)
18. Pando D, Caddeo C, Manconi M, Fadda AM, Pazos C. Nanodesign of olein vesicles for the topical delivery of the antioxidant resveratrol. J. Pharm. Pharmacol. 65 (8), 1158-1167 (2013).
19. Tavano L, Vivacqua M, Carito V, Muzzalupo R, Caroleo MC, Nicoletta F. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf. B Biointerfaces 102, 803-807 (2013).
20. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J. Pharm. Sci. 99, 2049-2060 (2010).
21. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS Pharm. Sci. Tech. 9, 740-747 (2008).
22. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS Pharm. Sci. Tech. 10 (4), 1186-1192 (2009).
23. Ruckmani K, Sankar V, Sivakumar M. Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. J. Biomed. Nanotechnol. 6, 43-51 (2010).
24. Marianeccia C, Paolino D, Celia C, Fresta M, Carafa M, Alhaique F. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fbroblasts. J. Control. Release 147, 127-135 (2010).
25. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int. J. Pharm. 290, 155-159 (2005). (Pubitemid 40139055)
26. Tamizharasi S, Dubey A, Rathi V, Rathi JC. Development and characterization of niosomal drug delivery of gliclazide. J. Young Pharm. 1, 205-209 (2009).
27. Carafa M, Santucci E, Lucania G. Lidocaine-loaded nonionic surfactant vesicles characterization and in vitro permeation studies. Int. J. Pharm. 231, 21-32 (2002). (Pubitemid 33086815)
28. Keservani RK, Sharma AK, Ramteke S. Novel vesicular approach for topical delivery of baclofen via niosomes. Lat. Am. J. Pharm. 29, 1364-1370 (2010).
29. Muller D, Foulon M, Bonnemain B, Vandamme TF. Niosomes as carriers of radiopaque contrast agents for X-ray imaging. J. Microencapsul. 17, 227-243 (2000). (Pubitemid 30135800)
30. Shataelebi MA, Mostafavi SA, Moghaddas A. Niosome as a drug carrier for topical delivery of N-acetyl glucosamine. Res. Pharm. Sci. 5(2), 107-117 (2010).
31. Desai AR, Raghuveer I, Chitme HR. Chandra R. Development and characterization of niosomal drug delivery of a-tocopherol. Int. J. Chem. Anal. Sci. 1, 146-158 (2010).
32. Huang Y, Chen J, Chen X, Gao J, Liang W. PEGylated synthetic surfactant vesicles (niosomes): novel carriers for oligonucleotides. J. Mater. Sci. Mater. Med. 19, 607-614 (2008). (Pubitemid 351244032)
33. Manosroi A, Thathang K, Werner RG, Schubert R, Manosroi J. Stability of luciferase plasmid entrapped in cationic bilayer vesicles. Int. J. Pharm. 356, 291-299 (2008).
34. He CX, Tabata Y, Gao JQ. Non-viral gene delivery carrier and its three-dimensional transfection system. Int. J. Pharm. 386, 232-242 (2010).
35. Paecharoenchai O, Niyomtham N, Ngawhirunpat T, Rojanarata T, Yingyongnarongkul B, Opanasopit P. Cationic niosomes composed of spermine-based cationic lipids mediate high gene transfection effciency. J. Drug Target. 20(9), 783-792 (2012).
36. Zhou C, Mao Y, Sugimoto Y et al. SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol. Pharm. 9, 201-210 (2012).
37. Zhou C, Zhang Y, Yu B, Phelps MA, Lee LJ, Lee RJ. Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. Nanomedicine 9(4), 504-513 (2013).
38. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems-an overview. Adv. Colloid Interface Sci. (183-184), 46-54 (2012).
39. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biol. Pharm. Bull. 34(7), 945-953 (2011).
40. Šegota S, Težak D. Spontaneous formation of vesicles. Adv. Colloid Interface Sci. 121, 51-75 (2006). (Pubitemid 44403910)
41. Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F. Vesicles of nonionic surfactants (niosomes) and drug delivery potential. Int. J. Pharm. Sci. Nanotechnol. 1, 1-8 (2008).
42. Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J. Pharm. Sci. 5, 220-225 (2002). (Pubitemid 37211713)
43. Nasr M, Mansour S, Mortada N, Elshamy AA. Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J. Microencapsul. 25(7), 499-512 (2008).
44. Pham TT, Jaafar-Maalej C, Charcosset C, Fessi H. Liposome and niosome preparation using a membrane contactor for scale-up. Colloids Surf. B Biointerfaces 94, 15-21 (2013).
45. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm. Sin. B 1(4), 208-219 (2011).
46. Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J. Appl. Pharm. Sci. 2(6), 20-32 (2012).
47. Wasungu L, Stuart MC, Scarzello M, Engberts JB, Hoekstra D. Lipoplexes formed from sugar-based gemini surfactants undergo a lamellar-to-micellar phase transition at acidic pH. Evidence for a non-inverted membrane-destabilizing hexagonal phase of lipoplexes. Biochim. Biophys. Acta 1758, 1677-1684 (2006). (Pubitemid 44466704)
48. Muzzalupo R, Tavano L, Trombino S, Cassano R, Picci N, La Mesa C. Niosomes from alpha, omega-trioxyethylene-bis(sodium 2-dodecyloxy- propylenesulfonate): preparation and characterization. Colloids Surf. B Biointerfaces 64(2), 200-207 (2008).
49. Muzzalupo R, Nicoletta FP, Trombino S, Cassano R, Iemma F, Picci N. A new crown ether as vesicular carrier for 5-fuoruracil: synthesis, characterization and drug delivery evaluation. Colloids Surf. B Biointerfaces 58(2), 197-202 (2007). (Pubitemid 46921457)
50. Yoshimura T, Hasegawa S, Hirashima N, Nakanishi M, Ohwada T. Anchoring and bola cationic amphiphiles for nucleotide delivery. Effects of orientation and extension of hydrophobic regions. Bioorg. Med. Chem. Lett. 11(22), 2897-2901 (2001). (Pubitemid 33000092)
51. Geusens B, Strobbe T, Bracke S et al. Lipid-mediated gene delivery to the skin. Eur. J. Pharm. Sci. 43, 199-211 (2011).
52. Manosroi A, Wongtrakul P, Manosroi J et al. Characterization of vesicles prepared with various nonionic surfactants mixed with cholesterol. J. Colloids Surf. B Biointerfaces 30, 129-138 (2003). (Pubitemid 36623337)
53. Nasseri B. Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int. J. Pharm. 300, 95-101 (2005). (Pubitemid 41112171)
54. Vyas SP, Singh R P, Jain S et al. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int. J. Pharm. 296, 80-86 (2005). (Pubitemid 40693375)
55. Perrie Y, Barralet JE, McNeil S, Vangala A. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int. J. Pharm. 284, 31-41 (2004). (Pubitemid 39349136)
56. Raghavachari N, Fahl WE. Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles. J. Pharm. Sci. 91(3), 615-622 (2002). (Pubitemid 34639624)
57. Manosroi J, Khositsuntiwong N, Manosroi W, Gotz F, Werner RG, Manosroi A. Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment. J. Pharm. Sci. 99(8), 3533-3541 (2010).
58. Huang Y, Rao Y, Chen J, Yang VC, Liang W. Polysorbate cationic synthetic vesicle for gene deliver. J. Biomed. Mater. Res. A 96, 513-519 (2011).
59. Huang YZ, Gao JQ, Chen JL, Liang WQ. Cationic liposomes modifed with nonionic surfactants as effective non-viral carrier for gene transfer. Colloids Surf. B. Biointerfaces 49(2), 158-164 (2006).
60. Pardakhty A, Shakibaie M, Daneshvar H, Khamesipour A, Mohammadi-Khors T, Forootanfar H. Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J. Microencapsul. 29(3), 219-224 (2011).
61. Vangala A, Bramwell V W, McNeil S, Christensen D, Agger EM, Perrie Y. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control. Release 119(1), 102-110 (2013).
62. Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv. 10, 251-262 (2003). (Pubitemid 37494139)
63. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm. 328, 130-141 (2007). (Pubitemid 44895483)
64. Manosroi A, Khanrin P, Werner RG, Götz F, Manosroi W, Manosroi J. Entrapment enhancement of peptide drugs in niosomes. J. Microencapsul. 27(3), 272-280 (2010).